At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 19 enrolled
Drug / intervention
Tedizolid phosphatedrug
Likely dose
Tedizolid phosphate 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Single Dose Pharmacokinetics of Intravenous Tedizolid Phosphate in Morbidly Obese and Age-, Sex-, and Ideal Body Weight-Matched Non-Obese Adults
In Brief
A Phase 4 clinical trial evaluating Tedizolid phosphate for Obesity. Completed, enrolled 19 participants.
Detailed Summary
This is an open label, single-dose, pharmacokinetic study in 9 obese and 9 age-, sex-, ideal body weight- matched non-obese subjects. Qualifying subjects who have completed an informed consent will receive a single intravenous dose of tedizolid with the collection of 11 blood samples over 72 hours post dose.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
Countries--
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 2015
Enrollment StartMar 2015
Primary CompletionSep 2015
Study CompletionDec 2015
TodayJul 2026
First PostedJan 21, 2015
Enrollment StartMar 1, 2015
Primary CompletionSep 1, 2015
Study CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 11.4 years ago
Interventions
Tedizolid phosphatedrug
Each group will receive a single dose of tedizolid phosphate 200 mg through a peripheral intravenous catheter.